Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.59 |
| ▸ | DRD3 | P35462 | 1/20 | 0.59 |
| ▸ | HTR1A | P08908 | 1/20 | 0.56 |
| ▸ | PRKACA | P17612 | 1/20 | 0.49 |
| ▸ | PRKACG | P22612 | 1/20 | 0.49 |
| ▸ | PRKACB | P22694 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5118709 | 0.82 | DRD2 (0.47) | DRD2DRD3 | |
| SCHEMBL2295355 | 0.82 | DRD2 (0.47) | DRD2DRD3 | |
| SCHEMBL2295207 | 0.82 | DRD2 (0.47) | DRD2DRD3 | |
| SCHEMBL177269 | 0.79 | LMNA (0.55) | LMNAKDM4EALDH1A1TSHRMEN1 | |
| SCHEMBL177270 | 0.79 | LMNA (0.55) | LMNAKDM4EALDH1A1TSHRMEN1 | |
| SCHEMBL16824940 | 0.79 | LMNA (0.55) | LMNAKDM4EALDH1A1TSHRMEN1 | |
| SCHEMBL27083132 | 0.78 | PRKACA (0.47) | DRD2DRD3HTR1APRKACAPRKACG | |
| SCHEMBL22089840 | 0.78 | DRD2 (0.41) | DRD2DRD3 | |
| SCHEMBL1336667 | 0.78 | CHRNB4 (0.45) | — | |
| SCHEMBL10792347 | 0.77 | KDM4E (0.49) | LMNAKDM4EALDH1A1TSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020119606-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR | GUANGDONG NEWOPP BIOPHARMACEUTICALS CO., LTD. (CN) | 2020-06-18 | — | — | WO | disclosed |
| US-8242115-B2 | Inhibit DNA-dependent protein kinase; reduced side effects caused by radiation and chemotherapy drugs | LUITPOLD PHARMACEUTICALS, INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-20080090782-A1 | Materials and methods to potentiate cancer treatment | LUITPOLD PHARMACEUTICALS, INC. (US) | 2008-04-17 | — | — | US | disclosed |
| US-7179912-B2 | Materials and methods to potentiate cancer treatment | ICOS CORPORATION (US) | 2007-02-20 | — | — | US | disclosed |
| EP-1351946-A2 | MATERIALS AND METHODS TO POTENTIATE CANCER TREATMENT | ICOS CORPORATION (US) | 2003-10-15 | — | — | EP | disclosed |
| US-20020165218-A1 | Materials and methods to potentiate cancer treatment | LUITPOLD PHARMACEUTICALS, INC. | 2002-11-07 | — | — | US | disclosed |
| WO-2002020500-A2 | MATERIALS AND METHODS TO POTENTIATE CANCER TREATMENT | ICOS CORPORATION (US) | 2002-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090782-A1 | Materials and methods to potentiate cancer treatment | DCK, CHEK2, CHEK1 | DRD2 4819/4885DRD3 4830/4885HTR1A 4472/4885 |
| US-20020165218-A1 | Materials and methods to potentiate cancer treatment | DCK, CHEK2, CHEK1 | DRD2 4819/4885DRD3 4830/4885HTR1A 4472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.